C4 Therapeutics Files 8-K on Sept 22

Ticker: CCCC · Form: 8-K · Filed: Sep 22, 2025 · CIK: 1662579

C4 Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyC4 Therapeutics, Inc. (CCCC)
Form Type8-K
Filed DateSep 22, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-disclosure, financial-reporting

TL;DR

C4 Therapeutics filed an 8-K on 9/22, check for updates.

AI Summary

C4 Therapeutics, Inc. filed an 8-K on September 22, 2025, reporting on events that occurred on September 20, 2025. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company is incorporated in Delaware and is in the biological products sector.

Why It Matters

This 8-K filing provides updates on C4 Therapeutics' corporate activities and financial reporting, which are crucial for investors to assess the company's current status and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant negative news or events.

Key Numbers

  • 001-39567 — SEC File Number (Identifies the company's filing history with the SEC.)
  • 47-5617627 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

  • C4 Therapeutics, Inc. (company) — Registrant
  • Delaware (jurisdiction) — State of Incorporation
  • September 22, 2025 (date) — Date of Report
  • September 20, 2025 (date) — Date of earliest event reported

FAQ

What specific events are detailed under 'Other Events' in this 8-K filing?

The provided text does not specify the details of the 'Other Events', only that it is an item reported in the 8-K.

Are there any financial statements included with this filing?

Yes, the filing lists 'Financial Statements and Exhibits' as an item information category.

What is the principal executive office address for C4 Therapeutics, Inc.?

The principal executive offices are located at 490 Arsenal Way, Suite 120, Watertown, MA 02472.

When was C4 Therapeutics, Inc. incorporated?

The filing states the company is incorporated in Delaware, but the specific incorporation date is not provided in this excerpt.

What is the SIC code for C4 Therapeutics, Inc.?

The Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).

Filing Stats: 732 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2025-09-22 06:41:16

Key Financial Figures

  • $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CCCC The Nasdaq Glo

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 20, 2025, C4 Therapeutics, Inc. (the " Company ") issued a press release announcing data from its Phase 1 clinical trial of cemsidomide, an orally bioavailable IKZF1/3 degrader, in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (" RRMM "), as presented in an oral presentation at the International Myeloma Society Annual Meeting (the " IMS Meeting "). A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, except as expressly set forth by specific reference in such a filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

01 Other Events

Item 8.01 Other Events. On September 20, 2025, the Company presented data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone for the treatment of RRMM in an oral presentation at the IMS Meeting. A copy of the slides from this presentation, which has been published to the "Events & Presentations" page of the investor relations section of the Company's website, is filed as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form. Exhibit Number Description 99.1 Press release issued September 20, 2025 99.2 Data presentation from International Myeloma Society Annual Meeting, dated September 20, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. C4 Therapeutics, Inc. Date: September 22, 2025 By: /s/ Jolie M. Siegel Jolie M. Siegel Chief Legal Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.